| 1999 | Vacc-4x first human trials |
| 2000 | Vaccine development spun off and Bionor Immuno AS established |
| 2004 | Grant of Vacc-4x patent in US |
| 2010-2011 | Vacc-4x demonstrated a reduction of viral load (secondary endpoint) of 64% in a 135-patient placebo controlled, randomized Phase II trial. Primary endpoints in the study not met so development put on hold until analysis of secondary endpoints were known. |
| 2011 | Research agreement with Celgene of Phase II trial of Revlimid and Vacc-4x |
| 2012 | Vacc-C5 first human trials – Phase I/II trial initiated |
| 2012 | Grant of funds from GLOBVAC and initiation of the Vacc-4x Phase II Reboost trial |
| 2013 | Launch of «Shock & Kill» therapeutic strategy |
| 2014 | Immunor AS incorporated in Norway (22 October) |
| 2015 | Romidepsin supply agreement with Celgene for BIOSKILL clinical trial |
| 2015 | Successful completion of the treatment phase of the REDUC clinical trial |
| 2018 | Preclinical proof of concept CRX (HIV Entry inhibitor) |
| 2020 | Biovacc-19 patent submitted (precursor to BioVac-19R) |
| 2020 | Biovacc-19 Preclinical study |
| 2020 | Preclinical study of Vacc-C5 with new adjuvant |
| 2021 | Licence agreement with Vulsana Ltd to develop neuropathy-wound healing injectable drug |
| 2023 | Development agreement with Professor Cecilia Nauclér on CMV oncogenic virus therapies |
| 2023 | All research and patents gathered under the Immunor platform |
